Pharmacy Times published one of the most clinically dense and practically important pieces of the year this week, featuring two clinical pharmacists presenting at the 2026 Association of Diabetes Care and Education Specialists Annual Meeting. The piece documents a shift in chronic kidney disease management that most practicing pharmacists haven’t fully absorbed yet, and that positions the pharmacist’s comprehensive medication review capability as the most valuable clinical function in the nephrology care team.
The Shift That Changed Everything
CKD management has moved from a single-drug, blood-pressure-focused intervention to a layered, four-class protocol. The renin-angiotensin-aldosterone system agent was the standard for decades: give an ACE inhibitor or ARB, control blood pressure, slow CKD progression, done. The evidence base for that approach was strong for its time. The evidence base for what replaces it is considerably stronger.
The current standard of care for CKD with proteinuria in type 2 diabetes now involves four distinct drug classes, staggered carefully over time and each targeting a different mechanistic driver of kidney disease progression.
Layer 1: Renin-Angiotensin System Agent. The ACE inhibitor or ARB remains the foundational layer. It reduces intraglomerular pressure, decreases proteinuria, and slows the progression of diabetic kidney disease through hemodynamic and non-hemodynamic mechanisms. This layer is non-negotiable in patients with significant proteinuria and CKD.
Layer 2: SGLT2 Inhibitor. Added for kidney protection independent of glycemic effect. The CREDENCE and DAPA-CKD trials established that SGLT2 inhibitors reduce the risk of kidney failure, death from kidney disease, and cardiovascular events in patients with CKD regardless of diabetes status. The 2026 ADA Standards, covered in this newsletter, repositioned SGLT2 inhibitors as core cardiorenal protective therapy independent of A1C. The initial eGFR decline of up to 30% that follows SGLT2 initiation is expected, acceptable, and does not represent kidney harm. Pharmacists who understand this prevent inappropriate discontinuation based on a lab value that looks alarming without clinical context.
Layer 3: GLP-1 Receptor Agonist. Added for cardiometabolic benefit and additional kidney protection. The FLOW trial, published in 2024, demonstrated that semaglutide reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and CKD, establishing GLP-1 therapy as a kidney-protective agent with a mechanism distinct from SGLT2 inhibitors. GLP-1s reduce kidney hyperfiltration, decrease glomerular inflammation, and lower cardiovascular risk, all of which contribute independently to slowing CKD progression.
Layer 4: Finerenone. The nonsteroidal mineralocorticoid receptor antagonist targets inflammatory and fibrotic pathways in kidney disease that the first three agents don’t fully address. This newsletter covered finerenone’s FDA Priority Review for its T1D-CKD indication in a prior issue. The FIDELIO-DKD and FIGARO-DKD trials established finerenone’s benefit in T2D-CKD. The drug’s mechanism is distinct from RAASi despite both targeting mineralocorticoid signaling, finerenone does so with greater selectivity and less hyperkalemia risk than traditional steroidal aldosterone antagonists like spironolactone.
The CONFIDENCE Trial Data That Changes the Sequencing Conversation
The classical approach sequences these agents one at a time, allowing lab values to stabilize after each addition before the next agent is introduced. That approach makes clinical sense from a monitoring standpoint but may delay benefit.
New Phase 2 CONFIDENCE trial data presented at ADCES 2026 suggests that simultaneous initiation of finerenone and an SGLT2 inhibitor may reduce albuminuria more than either agent alone, or may do so more rapidly than sequential initiation. This finding has not yet changed formal guideline recommendations, which still emphasize careful sequential titration. However, it has opened the clinical conversation about whether the monitoring infrastructure can support simultaneous initiation in selected patients, specifically those with baseline potassium below 4.5 mmol/L, stable eGFR, and existing RAASi therapy already at goal.
The SGLT2 inhibitor’s modest potassium-lowering effect, approximately 0.15 to 0.3 mEq/L reduction from baseline in most trials, partially offsets finerenone’s hyperkalemia risk. Whether that offset is sufficient to enable simultaneous initiation safely across the range of patient presentations seen in community practice is precisely the kind of clinical judgment question that a pharmacist managing the complete medication profile is best positioned to evaluate.
The Potassium Monitoring Imperative That Only a Pharmacist Tracks Comprehensively
The four-drug protocol creates a monitoring challenge that no single specialist manages completely, and that defines the pharmacist’s most critical function in this disease area.
A patient on an ACE inhibitor carries baseline hyperkalemia risk from RAASi blockade. The finerenone label requires potassium at or below 4.8 mEq/L before initiation, recheck at one month, and periodic monitoring thereafter. The SGLT2 inhibitor provides a modest potassium-lowering offset. The GLP-1 agonist is largely potassium-neutral but affects renal hemodynamics.
The combination of three agents with varying potassium effects, in a patient population that frequently also has reduced renal clearance of potassium due to CKD itself, produces a pharmacokinetic complexity that requires longitudinal, systematic monitoring rather than the episodic lab review that occurs at quarterly nephrology or endocrinology visits.
In the FIDELIO-DKD trial, 2.3% of patients in the finerenone arm experienced hyperkalemia leading to treatment discontinuation. In the real-world FINE-ONE T1D trial covered in this newsletter’s prior issue, 18.9% of patients on the highest finerenone dose experienced hyperkalemia. Those rates are manageable with systematic monitoring. Without it, hyperkalemia that develops between clinic visits goes undetected until it produces a clinical event.
The pharmacist managing a chronic disease panel who conducts monthly potassium review for patients on all four agents, flags trending elevations before they reach dangerous thresholds, and coordinates proactively with the prescribing team when potassium approaches the finerenone discontinuation threshold is performing a pharmacovigilance function that no other member of the care team performs systematically.
The CYP3A4 Interaction Layer Requiring Active Management
Finerenone’s CYP3A4 interaction profile, covered in the finerenone Priority Review issue of this newsletter, creates additional pharmacist responsibility in the four-drug protocol context.
Concomitant use of strong CYP3A4 inhibitors is contraindicated with finerenone. Moderate CYP3A4 inhibitors require dose reduction or enhanced monitoring. Strong or moderate CYP3A4 inducers should be avoided as they reduce finerenone exposure to potentially subtherapeutic levels. In a patient with CKD and type 2 diabetes who also has cardiovascular disease, may be taking statins, antifungals, antibiotics, or other medications metabolized through the CYP3A4 pathway, the interaction surveillance function requires reviewing the complete medication list.
The prescribing nephrologist or endocrinologist who adds finerenone to an existing regimen may not have visibility into the complete outpatient medication list, particularly if the patient fills prescriptions at multiple pharmacies or obtains some medications through mail-order. The pharmacist who sees the complete dispensing profile catches the interaction. The specialist who sees only what they prescribed does not.
The Treatment Gap as a Quality Metric and Billing Opportunity
The four-drug protocol represents both the highest standard of kidney-protective therapy for this patient population and a systematic quality measurement opportunity for pharmacists with access to a diabetes and CKD patient panel.
Current evidence demonstrates that appropriate use of RAASi, SGLT2 inhibitors, GLP-1 agonists, and finerenone substantially reduces kidney disease progression, cardiovascular events, and all-cause mortality in patients with type 2 diabetes and CKD. Despite this evidence, real-world prescribing lags substantially behind guideline recommendations. Studies consistently find that fewer than 30% of eligible patients with CKD and type 2 diabetes are on an SGLT2 inhibitor, and fewer than 10% are on finerenone.
Those gaps represent preventable kidney disease progression in patients who are already in your pharmacy. They also represent the same kind of quality metric gap that the JAMA pharmacist-led SGLT2 outreach study, covered in this newsletter, proved pharmacists can close. That study doubled SGLT2 inhibitor initiation rates in 8,600 veterans through systematic pharmacist outreach.
The same population health data approach applies to the four-drug protocol gap. A pharmacist who queries their patient panel for patients with type 2 diabetes and CKD diagnosis codes, reviews each patient’s current medication list against the four-agent standard, identifies the missing agents, and initiates a structured prescriber communication for each gap is performing guideline-concordant care gap closure that is documentable, billable under MTM and CMS ACCESS Model frameworks, and directly tied to patient outcomes.
The CMS ACCESS Model Connection
This newsletter covered the CMS ACCESS Model launch in July, documenting its focus on cardiometabolic conditions and its explicit naming of pharmacists as care coordination partners. The four-drug CKD protocol fits directly within the ACCESS Model’s CKM track, which covers type 2 diabetes and chronic kidney disease as a combined cardiometabolic disease category.
A pharmacist partnered with an ACCESS-participating organization, coordinating the initiation and monitoring of the four-drug CKD protocol for enrolled patients, is generating both clinical outcomes and ACCESS coordination payment. The monitoring functions, potassium tracking, eGFR surveillance, CYP3A4 interaction screening, and adherence support for all four agents, are exactly the between-visit clinical coordination that the ACCESS Model’s outcome-aligned payment was designed to incentivize.
The physician managing the same patient in a 15-minute quarterly nephrology appointment does not have the capacity to systematically review lab trends, identify interaction signals, and coordinate prescribing adjustments across four medication classes for a panel of 200 CKD patients. The pharmacist embedded in that care coordination infrastructure, reviewing lab data between visits and communicating findings to the prescriber before the next appointment, is providing continuous clinical oversight that the ACCESS outcome payment compensates precisely.
Your Clinical Audit This Week
Pull every patient in your panel with type 2 diabetes and a documented CKD diagnosis. The ICD-10 combination of E11.xx for type 2 diabetes and N18.xx for CKD identifies the target population from your dispensing system or EHR.
For each patient, run a four-agent audit:
Is the patient on an ACE inhibitor or ARB? If not, and they have proteinuria without contraindication, that is a treatment gap for prescriber communication.
Is the patient on an SGLT2 inhibitor? If not, what is their current eGFR? SGLT2 inhibitors are now indicated down to eGFR of 20 mL/min in the CKD protection indication for specific agents. A patient who was told years ago they couldn’t take an SGLT2 inhibitor because their eGFR was “too low” may now be eligible under current labeling.
Is the patient on a GLP-1 receptor agonist? FLOW trial data established semaglutide’s kidney-protective benefit. Patients with CKD who are not already on a GLP-1 for diabetes or cardiovascular risk have an unaddressed therapeutic gap.
Is the patient on finerenone? Before flagging this gap for prescriber communication, confirm the patient’s most recent potassium: at or below 4.8 mEq/L is required for initiation. Also screen for CYP3A4 inhibitor or inducer interactions in the current medication list.
Document each gap you identify and each prescriber communication you initiate. Under Medicare MTM billing requirements, comprehensive medication reviews that identify drug therapy problems and generate prescriber recommendations are documentable and billable encounters. Under the CMS ACCESS Model’s coordination framework, these documented interventions contribute to the outcome metrics that determine whether the participating organization receives full payment.
The four-drug protocol is the guideline standard. The gap between that standard and what most CKD patients receive is the pharmacist’s clinical opportunity. Identify it systematically. Act on it proactively. Document every step.
Sources: Pharmacy Times (Four-Drug Protocol for CKD Management: ADCES 2026 Clinical Pharmacist Presentation Coverage, August 2026), ADCES 2026 Annual Meeting (CKD Pharmacotherapy Session with Clinical Pharmacists), Lancet (FLOW Trial: Semaglutide and Kidney Outcomes in T2D and CKD, 2024), NEJM (FIDELIO-DKD and FIGARO-DKD Finerenone Trials), NEJM (CREDENCE Trial: Canagliflozin and Renal Outcomes in T2D and Nephropathy), Lancet Diabetes and Endocrinology (DAPA-CKD Trial: Dapagliflozin and CKD), Kidney International (CONFIDENCE Trial Phase 2: Finerenone Plus SGLT2 Inhibitor Combination, 2025), ADA Diabetes Care Journal (2026 Standards of Care: Section 10 Cardiovascular Disease, Cardiorenal Risk Reduction), Pharmacy Times (Finerenone Priority Review for T1D-CKD, June 2026), JAMA Network Open (Pharmacist-Led SGLT2 Outreach in VA Health Systems, 2026)